Drug name recognition (DNR) is an essential step in the Pharmacovigilance (PV) pipeline. DNR aims to find drug name mentions in unstructured biomedical texts and classify them into predefined categories. State-of-the-art DNR approaches heavily rely on hand-crafted features and domain-specific resources which are difficult to collect and tune. For this reason, this paper investigates the effectiveness of contemporary recurrent neural architectures – the Elman and Jordan networks and the bidirectional LSTM with CRF decoding – at performing DNR straight from the text. The experimental results achieved on the authoritative SemEval-2013 Task 9.1 benchmarks show that the bidirectional LSTM-CRF ranks closely to highly-dedicated, hand-crafted systems.
- RoZetta’s global commercialisation success story continues with sale of Lorica Health
- When High-frequency Traders Stay Isolated For COVID-19
- The “end” of roaring 2010’s yield-enhancing strategies – a Buy-Side perspective
- Measuring the influence of COVID-19 on the Australian property sector
- How RoZetta Institute research limits the impact of flash crashes